Individual Change in Methylphenidate Use in a National Sample of Children Aged 2 to 11 Years

Abstract

French

Objectives:

To determine methylphenidate use in children aged 2 to 13 years. To provide age- and sex-specific estimates of methylphenidate initiation and cessation during a 2-year period.

Method:

Data from 2 cycles of a Canadian household survey yielded a sample of over 10 000 children aged 2 to 11 years at Cycle 1 who continued to participate at Cycle 2. We used logit modelling to estimate Cycle 2 methylphenidate use, methylphenidate use over a 2-year period, and methylphenidate initiation and cessation from Cycles 1 to 2.

Results:

In 1996 and 1997, methylphenidate use ranged from 0.32% to 6.31% among children aged 4 to 13 years. School-aged boys were more likely than girls to use methylphenidate. Odds were greater for boys aged 6 to 7 years than for boys aged 4 to 5 years; they were also greater for boys aged 10 to 11 years than for boys aged 12 to 13 years. Almost 1% of children used methylphenidate at both data cycles. Odds of Cycle 2 methylphenidate use were 135 times greater for children using methylphenidate at Cycle 1, compared with nonusers. Methylphenidate initiation ranged from 0.20% to 3.34%, and school-aged boys had higher initiation rates than girls. Cessation rates ranged from 18% to 78%, and there were no statistically significant differences by age and sex.

Conclusions:

Methylphenidate prevalence findings are consistent with past studies. We found an age-by-sex interaction on methylphenidate use. We also found both continuity and discontinuity in methylphenidate use.

Keywords

methylphenidate stimulant use general population sample age effects sex effects prevalence initiation cessation

References

Brownell

Yogendran

. Attention-deficit hyperactivity disorder in Manitoba children: Medical diagnosis and psychostimulant treatment rates. Can J Psychiatry 2001;46:264–72.

Romano

Baillargeon

Robaey

Tremblay

. Methylphenidate prevalence and change over a two-year period: A nation-wide study of 2–11 year old Canadian children. J Pediatr 2002;141:71–5.

Robison

Sclar

Skaer

Galin

. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clin Pediatr 1999;38:209–17.

Zito

Safer

dos Reis

Gardner

Boles

Lynch

Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1025–30.

Zito

Safer

dos Reis

Gardner

Magder

Soeken

, and others. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17–25.

Jensen

Kettle

Roper

Sloan

Dulcan

Hoven

, and others. Are stimulants overprescribed? Treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 1999;38:797–804.

Rowland

Umbach

Stallone

Naftel

Bohlig

Sandler

. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 2002;92:231–4.

LeFever

Dawson

Morrow

. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health 1999;89:1359–64.

Safer

Malever

Stimulant treatment in Maryland public schools. Pediatrics 2000;106:533–9.

10.

Greenhill

Findling

Swanson

. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39.

11.

Kent

Camfield

. Double-blind methylphenidate trials: Practical, useful, and highly endorsed by families. Arch Pediatr Adolesc Med 1999;153:1292–6.

12.

Zeiner

Bryhn

Bjercke

Truyen

Strand

Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatr 1999;88:298–303.

13.

Findling

Short

Manos

. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2001;40:1441–7.

14.

Jensen

Hinshaw

Swanson

Greenhill

Conners

Arnold

, and others. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60–73.

15.

MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073–86.

16.

MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1088–96.

17.

Connor

. Preschool attention deficit hyperactivity disorder: A review of prevalence, diagnosis, neurobiology, and stimulant treatment. J Dev Behav Pediatr 2002;23:S1–S9.

18.

Gilmore

Milne

Methylphenidate in children with hyperactivity: Review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001;10:85–94.

19.

Greenhill

Halperin

Abikoff

Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999;38:503–12.

20.

Hechtman

Predictors of long-term outcome in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999;46:1039–52.

21.

Schachter

Pham

King

Langford

Moher

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001;165:1475–88.

22.

Spencer

Biederman

Wilens

Harding

O'Donnell

Griffin

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409–32.

23.

Greenhill

Pliszka

Dulcan

, and The Work Group on Quality Issues Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S–49S.

24.

Hechtman

Greenfield

Long-term use of stimulants in children with attention deficit hyperactivity disorder: Safety, efficacy, and long-term outcome. Paediatr Drugs 2003;5:787–94.

25.

American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder, Committee on Quality Improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033–44.

26.

Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties: The Canadian drug reference for health professionals. Ottawa: Canadian Pharmacists Association; 2004. p 1786–7.

27.

Breton

Bergeron

Valla

Berthiaume

Gaudet

Lambert

, and others. Quebec Child Mental Health Survey: Prevalence of DSM-III-R mental health disorders. J Child Psychol Psychiatry 1999;40:375–84.

28.

Gomez

Harvey

Quick

Scharer

Harris

DSM-IV AD/HD: Confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry 1999;40:265–74.

29.

Nolan

Gadow

Sprafkin

Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in school children. J Am Acad Child Adolesc Psychiatry 2001;40:241–9.

30.

Offord

Boyle

Szatmari

Rae-Grant

Links

Cadman

, and others. Ontario Child Health Study: II. Six-month prevalence of disorder and rates of service utilization. Arch Gen Psychiatry 1987;44:832–6.

31.

Offord

Boyle

Racine

Ontario Child Health Study: Correlates of disorder. J Am Acad Child Adolesc Psychiatry 1989;28:856–60.

32.

Pineda

Ardila

Rosselli

Arias

Henao

Gomez

, and others. Prevalence of attention-deficit/hyperactivity disorder symptoms in 4- to 17-year-old children in the general population. J Abnorm Child Psychol 1999;27:455–62.

33.

Scahill

Schwab-Stone

Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 2000;9:541–55.

34.

Szatmari

Offord

Boyle

. Ontario Child Health Study: Prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry 1989;30:219–30.

35.

Wolraich

Hannah

Pinnock

Baumgaertel

Brown

Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996;35:319–24.

36.

Broidy

Nagin

Tremblay

Bates

Brame

Dodge

, and others. Developmental trajectories of childhood disruptive behaviors and adolescent delinquency: A six-site, cross-national study. Dev Psychol 2003;39:222–45.

37.

Côté

Tremblay

Nagin

Zoccolillo

Vitaro

Childhood behavioral profiles leading to adolescent conduct disorder: Risk trajectories for boys and girls. J Am Acad Child Adolesc Psychiatry 2002;41:1086–94.

38.

Nagin

Tremblay

. Trajectories of boys' physical aggression, opposition, and hyperactivity on the path to physically violent and nonviolent juvenile delinquency. Child Dev 1999;70:1181–96.

39.

Statistics Canada and Human Resources Development Canada. National Longitudinal Survey of Children and Youth: Overview of survey instruments for 1994–1995 data collection cycle 1. Ottawa: Statistics Canada and Human Resources Development Canada; 1995.

40.

Statistics Canada and Human Resources Development Canada. National Longitudinal Survey of Children and Youth: Overview of survey instruments for 1996–1997 data collection cycle 2. Ottawa: Statistics Canada and Human Resources Development Canada; 1997.

41.

Fienberg

. The analysis of cross-classified categorical data. 2nd ed. Cambridge (MA): MIT Press; 1980.

42.

Vermunt

. lEM: A general program for the analysis of categorical data [computer program]. Tilburg (NE): Tilburg University; 1997.

43.

Safer

Zito

Fine

. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996;94:462–4.

44.

Rappley

Gardiner

Jetton

Houang

. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 1995;149:675–9.

45.

Zito

Safer

dos Reis

Magder

Riddle

. Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull. 1997;33:148–57.

46.

Zito

Safer

Riddle

Johnson

Speedie

Fox

Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol 1998;8:99–105.

47.

Baillargeon

Tremblay

Willms

Romano

Lee

. Modeling intraindividual change over time in the absence of a “gold standard.” Psychol Sci 2004;46:7–34.

48.

Baillargeon

Tremblay

Zoccolillo

Pérusse

Boivin

Japel

, and others. Intraindividual change in behaviour from 17 to 29 months of age. Quebec Longitudinal Study of Child Development (QLSCD 1998–2002) from birth to 29 months. Quebec: Institut de la statistique du Quebec; 2002.